stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Total debt
Grifols, S.A.'s total debt at the end of fiscal 2025 was $10.9B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $10.6B. Over the past ten years it has ranged from $5.3B (fiscal 2016) to $12.1B (fiscal 2021); the current reading is higher than 67% of that period. Grifols, S.A. ranks 14th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $10.9B | (0.83%) |
| FY2024 | $11.0B | (8.07%) |
| FY2023 | $12.0B | 5.60% |
| FY2022 | $11.3B | 2.29% |
| FY2022 | $11.1B | (8.25%) |
| FY2021 | $12.1B | 4.91% |
| FY2021 | $11.5B | 43.41% |
| FY2020 | $8.0B | 3.35% |
| FY2020 | $7.8B | (3.81%) |
| FY2019 | $8.1B | (1.15%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $10.6B | (2.23%) |
| Jun 2026 | $10.9B | (3.87%) |
| Mar 2026 | $11.3B | 3.73% |
| Dec 2025 | $10.9B | (3.66%) |
| 31 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BMY Bristol Myers Squibb Company compare | $42.9B |
| GSK GSK PLC Sponsored ADR compare | $31.9B |
| NVO Novo Nordisk A/S compare | $20.7B |
| SNY Sanofi compare | $20.7B |
| GRFS Grifols, S.A. | $10.6B |
| OGN Organon & Co. compare | $8.6B |
| BIIB Biogen Inc. compare | $7.3B |
| AMRN Amarin Corporation PLC compare | $9.0M |
| NSRX Nasus Pharma Ltd. compare | $2.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement